Benralizumab effectively reduces severe eosinophilic asthma (SEA) exacerbations in patients with a wide range of baseline blood eosinophil count (BEC). Patients included in real-world studies are often characterized by high mean/median BEC, while patients with BEC close to 300 cells/mm3 are poorly represented. This post hoc analysis from the Italian study ANANKE aims to define the clinical features and corroborate the efficacy of benralizumab in real world in the BEC 300-450 cells/mm3 subset of patients.

Clinical Features and Efficacy of Benralizumab in Patients with Blood Eosinophil Count Between 300 and 450 Cells/mm3: A Post Hoc Analysis from the ANANKE Study / G. Senna, M. Aliani, E. Altieri, P. Bracciale, L. Brussino, M.F. Caiaffa, P. Cameli, G.W. Canonica, C. Caruso, M. D'Amato, F. De Michele, S. Del Giacco, F. Di Marco, F. Menzella, G. Pelaia, P. Rogliani, M. Romagnoli, P. Schino, J.W. Schroeder, A. Vultaggio, S. Rizzoli, A. Zullo, S. Boarino, M. Palmisano, A. Rossi, G. Vitiello, S. Centanni. - In: JOURNAL OF ASTHMA AND ALLERGY. - ISSN 1178-6965. - 15:(2022), pp. 1593-1604. [10.2147/JAA.S383012]

Clinical Features and Efficacy of Benralizumab in Patients with Blood Eosinophil Count Between 300 and 450 Cells/mm3: A Post Hoc Analysis from the ANANKE Study

F. Di Marco;S. Centanni
Ultimo
2022

Abstract

Benralizumab effectively reduces severe eosinophilic asthma (SEA) exacerbations in patients with a wide range of baseline blood eosinophil count (BEC). Patients included in real-world studies are often characterized by high mean/median BEC, while patients with BEC close to 300 cells/mm3 are poorly represented. This post hoc analysis from the Italian study ANANKE aims to define the clinical features and corroborate the efficacy of benralizumab in real world in the BEC 300-450 cells/mm3 subset of patients.
benralizumab; blood eosinophil count; observational; real-life; real-world evidence; severe eosinophilic asthma
Settore MED/10 - Malattie dell'Apparato Respiratorio
Article (author)
File in questo prodotto:
File Dimensione Formato  
JAA-383012-clinical-features-and-efficacy-of-benralizumab-in-patients-w.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 1.96 MB
Formato Adobe PDF
1.96 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/946766
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact